These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23255391)

  • 21. Outcome of pediatric non-Hodgkin lymphoma in Central America: A report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA).
    Peña-Hernandez A; Ortiz R; Garrido C; Gomez-Garcia W; Fuentes-Alabi S; Martinez R; Metzger ML; Chantada GL; Ribeiro RC
    Pediatr Blood Cancer; 2019 May; 66(5):e27621. PubMed ID: 30677231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric classical Hodgkin lymphoma.
    Lo AC; Dieckmann K; Pelz T; Gallop-Evans E; Engenhart-Cabillic R; Vordermark D; Kelly KM; Schwartz CL; Constine LS; Roberts K; Hodgson D
    Pediatr Blood Cancer; 2021 May; 68 Suppl 2():e28562. PubMed ID: 33818890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment and prognosis of children with relapsed non-Hodgkin's lymphoma--a report from CCLSG-NHL 890 Study. Children's Cancer and Leukemia Study Group (CCLSG)].
    Tsurusawa M; Katano N; Asami K; Watanabe A; Koizumi S; Miyake M; Kikuta A; Iwai A; Yamamura Y; Kawano Y; Mugishima H; Sekine I; Matsushita T; Horikoshi Y; Kikuchi M; Anami K; Fujimoto T
    Gan To Kagaku Ryoho; 2000 Oct; 27(11):1695-702. PubMed ID: 11057320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapeutic Management of Pediatric Lymphoma.
    Mauz-Körholz C; Ströter N; Baumann J; Botzen A; Körholz K; Körholz D
    Paediatr Drugs; 2018 Feb; 20(1):43-57. PubMed ID: 29127674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience.
    Rybka J; Jurczak W; Giza A; Paszkiewicz-Kozik E; Kumiega B; Drozd-Sokołowska J; Butrym A; Kuliczkowski K; Wróbel T
    Adv Clin Exp Med; 2015; 24(5):783-9. PubMed ID: 26768628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Barth MJ; Minard-Colin V
    Br J Haematol; 2019 Jun; 185(6):1111-1124. PubMed ID: 30701541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma.
    Fanale M; Assouline S; Kuruvilla J; Solal-Céligny P; Heo DS; Verhoef G; Corradini P; Abramson JS; Offner F; Engert A; Dyer MJ; Carreon D; Ewald B; Baeck J; Younes A; Freedman AS
    Br J Haematol; 2014 Jan; 164(2):258-65. PubMed ID: 24219359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Children's Oncology Group's 2013 blueprint for research: central nervous system tumors.
    Gajjar A; Packer RJ; Foreman NK; Cohen K; Haas-Kogan D; Merchant TE;
    Pediatr Blood Cancer; 2013 Jun; 60(6):1022-6. PubMed ID: 23255213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What is the role of autologous transplant for lymphoma in the current era?
    Stiff P
    Hematology Am Soc Hematol Educ Program; 2015; 2015():74-81. PubMed ID: 26637704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
    Mukherji D; Pettengell R
    Expert Opin Pharmacother; 2010 Aug; 11(11):1915-23. PubMed ID: 20569087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Semen quality in non-Hodgkin lymphoma survivors: a monocentric retrospective study.
    Pallotti F; Pelloni M; Faja F; Di Chiano S; Di Rocco A; Lenzi A; Lombardo F; Paoli D
    Hum Reprod; 2021 Jan; 36(1):16-25. PubMed ID: 33257989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded).
    Sullivan MP; Boyett J; Pullen J; Crist W; Doering EJ; Trueworthy R; Hvizdala E; Ruymann F; Steuber CP
    Cancer; 1985 Jan; 55(2):323-36. PubMed ID: 3880656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 1.
    Siddiqi T; Rosen ST
    Oncology (Williston Park); 2015 Mar; 29(3):198-203. PubMed ID: 25772456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials.
    Kahn JM; Pei Q; Friedman DL; Kaplan J; Keller FG; Hodgson D; Wu Y; Appel BE; Bhatia S; Henderson TO; Schwartz CL; Kelly KM; Castellino SM
    Lancet Haematol; 2022 Jan; 9(1):e49-e57. PubMed ID: 34971582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.
    Boyle EM; Morschhauser F
    Expert Opin Drug Saf; 2015 Apr; 14(4):601-7. PubMed ID: 25716061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology.
    Márky I; Björk O; Forestier E; Jónsson OG; Perkkiö M; Schmiegelow K; Storm-Mathiesen I; Gustafsson G;
    J Pediatr Hematol Oncol; 2004 Sep; 26(9):555-60. PubMed ID: 15342981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Children's Oncology Group's 2023 blueprint for research: Cancer control and supportive care.
    Esbenshade AJ; Sung L; Brackett J; Dupuis LL; Fisher BT; Grimes A; Miller TP; Ullrich NJ; Dvorak CC;
    Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30568. PubMed ID: 37430431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Children's Oncology Group's 2013 blueprint for research: survivorship and outcomes.
    Armenian SH; Landier W; Hudson MM; Robison LL; Bhatia S;
    Pediatr Blood Cancer; 2013 Jun; 60(6):1063-8. PubMed ID: 23255494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.